Radiation plus darolutamide and degarelix for intermediate prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 trial tests whether adding darolutamide and degarelix to radiation can improve outcomes in men with intermediate-risk prostate cancer. If you fit the cancer and health criteria, it may offer a way to treat the cancer more aggressively than radiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be male and age 18 or older
- Have prostate cancer confirmed by biopsy within the last 6 months
- Have a recent PSA blood test (within 60 days) and be in the trial’s intermediate-risk category
- Have scans showing no spread to bones (bone scan within 4 months) and no spread to pelvic lymph nodes (pelvic CT or MRI within 4 months)
- Have not taken hormone therapy for prostate cancer in the past year (including shots like degarelix/leuprolide or pills like bicalutamide/finasteride)
- Have safe bloodwork and organ function (not severely low hemoglobin/platelets, low albumin, or significant kidney/liver problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.